Effect of combined COX-1 and COX-2 inhibition on platelet aggregation in-vivo

Effect of combined COX-1 and COX-2 inhibition on platelet aggregation in-vivo - Effect of COX-2 inhibition on platelet aggregation in-vivo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30233

Enrollment

Registered

2006-12-04

Start date

2006-09-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

enhanced clotting thrombosis

Interventions

Canulation of an antecubital vein. Intake of aspirin

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy men

Exclusion criteria

Exclusion criteria: Use of medical drugs, smoking, supersensitivity to aspirin

Design outcomes

Primary

Measure	Time frame
Amount of aggregation to ADP and epinephrine before and after aspirin at some seconds after the blood left the canula	—

Secondary

Measure	Time frame
Amount of aggregation to ADP and arachidonic acid before and after aspirin in a whole blood aggregopmeter , at more than one hour after blood collection	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)